Literature DB >> 28089910

Glioblastoma Cancer Stem Cells Evade Innate Immune Suppression of Self-Renewal through Reduced TLR4 Expression.

Alvaro G Alvarado1, Praveena S Thiagarajan2, Erin E Mulkearns-Hubert2, Daniel J Silver2, James S Hale2, Tyler J Alban1, Soumya M Turaga2, Awad Jarrar2, Ofer Reizes3, Michelle S Longworth2, Michael A Vogelbaum4, Justin D Lathia5.   

Abstract

Tumors contain hostile inflammatory signals generated by aberrant proliferation, necrosis, and hypoxia. These signals are sensed and acted upon acutely by the Toll-like receptors (TLRs) to halt proliferation and activate an immune response. Despite the presence of TLR ligands within the microenvironment, tumors progress, and the mechanisms that permit this growth remain largely unknown. We report that self-renewing cancer stem cells (CSCs) in glioblastoma have low TLR4 expression that allows them to survive by disregarding inflammatory signals. Non-CSCs express high levels of TLR4 and respond to ligands. TLR4 signaling suppresses CSC properties by reducing retinoblastoma binding protein 5 (RBBP5), which is elevated in CSCs. RBBP5 activates core stem cell transcription factors, is necessary and sufficient for self-renewal, and is suppressed by TLR4 overexpression in CSCs. Our findings provide a mechanism through which CSCs persist in hostile environments because of an inability to respond to inflammatory signals.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  RBBP5; TLR4; cancer stem cells; glioblastoma; innate immunity; pluripotency transcription factors

Mesh:

Substances:

Year:  2017        PMID: 28089910      PMCID: PMC5822422          DOI: 10.1016/j.stem.2016.12.001

Source DB:  PubMed          Journal:  Cell Stem Cell        ISSN: 1875-9777            Impact factor:   24.633


  50 in total

1.  Toll-like receptors modulate adult hippocampal neurogenesis.

Authors:  Asya Rolls; Ravid Shechter; Anat London; Yaniv Ziv; Ayal Ronen; Rinat Levy; Michal Schwartz
Journal:  Nat Cell Biol       Date:  2007-08-19       Impact factor: 28.824

2.  Involvement of TNFα-induced TLR4-NF-κB and TLR4-HIF-1α feed-forward loops in the regulation of inflammatory responses in glioma.

Authors:  Richa Tewari; Saurav Roy Choudhury; Sadashib Ghosh; Veer Singh Mehta; Ellora Sen
Journal:  J Mol Med (Berl)       Date:  2011-09-02       Impact factor: 4.599

3.  GlioVis data portal for visualization and analysis of brain tumor expression datasets.

Authors:  Robert L Bowman; Qianghu Wang; Angel Carro; Roel G W Verhaak; Massimo Squatrito
Journal:  Neuro Oncol       Date:  2016-11-09       Impact factor: 12.300

4.  Acidic stress promotes a glioma stem cell phenotype.

Authors:  A B Hjelmeland; Q Wu; J M Heddleston; G S Choudhary; J MacSwords; J D Lathia; R McLendon; D Lindner; A Sloan; J N Rich
Journal:  Cell Death Differ       Date:  2010-12-03       Impact factor: 15.828

5.  TLR9 is critical for glioma stem cell maintenance and targeting.

Authors:  Andreas Herrmann; Gregory Cherryholmes; Anne Schroeder; Jillian Phallen; Darya Alizadeh; Hong Xin; Tianyi Wang; Heehyoung Lee; Christoph Lahtz; Piotr Swiderski; Brian Armstrong; Claudia Kowolik; Gary L Gallia; Michael Lim; Christine Brown; Behnam Badie; Stephen Forman; Marcin Kortylewski; Richard Jove; Hua Yu
Journal:  Cancer Res       Date:  2014-07-21       Impact factor: 12.701

6.  TLR4 signal transduction pathways neutralize the effect of Fas signals on glioblastoma cell proliferation and migration.

Authors:  Vincent Sarrazy; Nicolas Vedrenne; Fabrice Billet; Nelly Bordeau; Sébastien Lepreux; Anne Vital; Marie-Odile Jauberteau; Alexis Desmoulière
Journal:  Cancer Lett       Date:  2011-07-23       Impact factor: 8.679

7.  A tumorigenic MLL-homeobox network in human glioblastoma stem cells.

Authors:  Marco Gallo; Jenny Ho; Fiona J Coutinho; Robert Vanner; Lilian Lee; Renee Head; Erick K M Ling; Ian D Clarke; Peter B Dirks
Journal:  Cancer Res       Date:  2012-10-29       Impact factor: 12.701

8.  Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells.

Authors:  Zhizhong Li; Shideng Bao; Qiulian Wu; Hui Wang; Christine Eyler; Sith Sathornsumetee; Qing Shi; Yiting Cao; Justin Lathia; Roger E McLendon; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cancer Cell       Date:  2009-06-02       Impact factor: 31.743

9.  Human Colon Tumors Express a Dominant-Negative Form of SIGIRR That Promotes Inflammation and Colitis-Associated Colon Cancer in Mice.

Authors:  Junjie Zhao; Katarzyna Bulek; Muhammet F Gulen; Jarod A Zepp; Georgio Karagkounis; Bradley N Martin; Hao Zhou; Minjia Yu; Xiuli Liu; Emina Huang; Paul L Fox; Matthew F Kalady; Sanford D Markowitz; Xiaoxia Li
Journal:  Gastroenterology       Date:  2015-09-05       Impact factor: 22.682

10.  A restricted cell population propagates glioblastoma growth after chemotherapy.

Authors:  Jian Chen; Yanjiao Li; Tzong-Shiue Yu; Renée M McKay; Dennis K Burns; Steven G Kernie; Luis F Parada
Journal:  Nature       Date:  2012-08-23       Impact factor: 49.962

View more
  64 in total

Review 1.  TLR-4 Signaling vs. Immune Checkpoints, miRNAs Molecules, Cancer Stem Cells, and Wingless-Signaling Interplay in Glioblastoma Multiforme-Future Perspectives.

Authors:  Jakub Litak; Cezary Grochowski; Joanna Litak; Ida Osuchowska; Krzysztof Gosik; Elżbieta Radzikowska; Piotr Kamieniak; Jacek Rolinski
Journal:  Int J Mol Sci       Date:  2020-04-28       Impact factor: 5.923

2.  Targeting of BMI-1 with PTC-209 inhibits glioblastoma development.

Authors:  Yu Kong; Chunbo Ai; Feng Dong; Xianyou Xia; Xiujuan Zhao; Chao Yang; Chunsheng Kang; Yan Zhou; Qian Zhao; Xiujing Sun; Xudong Wu
Journal:  Cell Cycle       Date:  2018-07-23       Impact factor: 4.534

3.  Engineering Controlled Peritumoral Inflammation to Constrain Brain Tumor Growth.

Authors:  Tarun Saxena; Johnathan G Lyon; S Balakrishna Pai; Daniel Pare; Jessica Amero; Lohitash Karumbaiah; Sheridan L Carroll; Eric Gaupp; Ravi V Bellamkonda
Journal:  Adv Healthc Mater       Date:  2018-12-11       Impact factor: 9.933

Review 4.  Brain Tumor Stem Cells Remain in Play.

Authors:  Luis F Parada; Peter B Dirks; Robert J Wechsler-Reya
Journal:  J Clin Oncol       Date:  2017-06-22       Impact factor: 44.544

5.  Repurposing FDA approved drugs inhibiting mitochondrial function for targeting glioma-stem like cells.

Authors:  Sandipan Datta; Thomas Sears; Gino Cortopassi; Kevin Woolard; James M Angelastro
Journal:  Biomed Pharmacother       Date:  2020-12-08       Impact factor: 6.529

Review 6.  Engineering challenges for brain tumor immunotherapy.

Authors:  Johnathan G Lyon; Nassir Mokarram; Tarun Saxena; Sheridan L Carroll; Ravi V Bellamkonda
Journal:  Adv Drug Deliv Rev       Date:  2017-06-15       Impact factor: 15.470

7.  TLR4 in glioblastoma-when cancer stem cells ignore "danger signals".

Authors:  Christoph P Beier; Bjarne W Kristensen
Journal:  Stem Cell Investig       Date:  2017-07-25

Review 8.  Potentiating prostate cancer immunotherapy with oncolytic viruses.

Authors:  Patrick Lee; Shashi Gujar
Journal:  Nat Rev Urol       Date:  2018-02-13       Impact factor: 14.432

Review 9.  TLR4 Polymorphisms and Expression in Solid Cancers.

Authors:  Nilesh Pandey; Alex Chauhan; Neeraj Jain
Journal:  Mol Diagn Ther       Date:  2018-12       Impact factor: 4.074

Review 10.  Cancer Stem Cells: The Architects of the Tumor Ecosystem.

Authors:  Briana C Prager; Qi Xie; Shideng Bao; Jeremy N Rich
Journal:  Cell Stem Cell       Date:  2019-01-03       Impact factor: 24.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.